Targeted small interfering RNA-immunoliposomes as a promising therapeutic agent against highly pathogenic avian influenza A (H5N1) virus infection

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 5, 2014, Pages 2816-2824

  Khantasup, Kannika ^a,b   Kopermsub, Phikulthong ^b   Chaichoun, Kridsada ^c   Dharakul, Tararaj ^a,b  

^a MAHIDOL UNIVERSITY   (Thailand)

^b NATIONAL SCIENCE AND TECHNOLOGY DEVELOPMENT AGENCY   (Thailand)

^c MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

3BETA [N(N',N' DIMETHYLAMINOETHANE)CARBAMOYL]CHOLESTEROL DIOLEOYLPHOSPHATIDYL ETHANOLAMINE; IMMUNOLIPOSOME; MESSENGER RNA; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VIRUS HEMAGGLUTININ; VIRUS NUCLEOPROTEIN; ANTIVIRUS AGENT; LIPOSOME;

ANIMAL CELL; ARTICLE; AVIAN INFLUENZA VIRUS; CONTROLLED STUDY; DRUG TARGETING; GENE SILENCING; GENETIC TRANSFECTION; INFLUENZA A (H5N1); INFLUENZA VIRUS A H5N1; LIPOSOMAL GENE DELIVERY SYSTEM; MDCK CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PARTICLE SIZE; PRIORITY JOURNAL; SF9 CELL; TARGET CELL; VIRUS INHIBITION; ZETA POTENTIAL; ANIMAL; CELL LINE; CELL SURVIVAL; CHEMISTRY; DOG; DRUG EFFECTS; FLOW CYTOMETRY; GENETICS; PATHOGENICITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; CELL SURVIVAL; DOGS; FLOW CYTOMETRY; INFLUENZA A VIRUS, H5N1 SUBTYPE; LIPOSOMES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; SINGLE-CHAIN ANTIBODIES;

EID: 84898669965     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02768-13     Document Type: Article

References (40)

1. World Organisation for Animal Health. 2012. Update on highly pathogenic avian influenza in animals (type H5 and H7). World Organisation for Animal Health, Paris, France. http://www.oie.int/animal-health-in-the-world/update-on- Avian-influenza/2013/. Accessed April 2013.
2. World Health Organization. 2013. Cumulative number of confirmed human cases for avian influenza A(H5N1) reported to WHO, 2003-2013. World Health Organization, Geneva, Switzerland. http://www.who.int/in fluenza/human-Animal- interface/EN-GIP-20130426CumulativeNumb erH5N1cases.pdf. Accessed April 2013.
3. Le QM, Kiso M, Someya K, Sakai YT, Nguyen TH, Nguyen KH, Pham ND, Ngyen HH, Yamada S, Muramoto Y, Horimoto T, Takada A, Goto H, Suzuki T, Suzuki Y, Kawaoka Y. 2005. Avian flu: isolation of drugresistant H5N1 virus. Nature 437:1108. http://dx.doi.org/10.1038/4371 108a.
4. Motavaf M, Safari S, Alavian SM. 2012. Therapeutic potential of RNA interference: a new molecular approach to antiviral treatment for hepatitis C. J. Viral Hepat. 19:757-765. http://dx.doi.org/10.1111/jvh.12006.
5. Spurgers KB, Sharkey CM, Warfield KL, Bavari S. 2008. Oligonucleotide antiviral therapeutics: antisense and RNA interference for highly pathogenic RNA viruses. Antiviral Res. 78:26-36. http://dx.doi.org/10.1016/j.antiviral.2007. 12.008.
6. Davidson BL, McCray PB, Jr. 2011. Current prospects for RNA interference-based therapies. Nat. Rev. Genet. 12:329-340. http://dx.doi.org/10. 1038/nrg2968.
7. Barik S. 2010. siRNA for influenza therapy. Viruses 2:1448-1457. http://dx.doi.org/10.3390/v2071448.
8. McSwiggen JA, Seth S. 2008. A potential treatment for pandemic influenza using siRNAs targeting conserved regions of influenza A. Expert Opin. Biol. Ther. 8:299-313. http://dx.doi.org/10.1517/14712598.8.3.299.
9. Trehan S, Sharma G, Misra A. 2010. siRNA: sojourn from discovery to delivery challenges and clinics. Syst. Rev. Pharm. 1:1-16. http://dx.doi.org/10. 4103/0975-8453.59507.
10. Mamot C, Drummond DC, Greiser U, Hong K, Kirpotin DB, Marks JD, Park JW. 2003. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR-And EGFRvIII-overexpressing tumor cells. Cancer Res. 63:3154-3161. http://cancerres.aacrjournals.org/content/63/ 12/3154.
11. Pirollo KF, Zon G, Rait A, Zhou Q, Yu W, Hogrefe R, Chang EH. 2006. Tumor-targeting nanoimmunoliposome complex for short interfering RNA delivery. Hum. Gene Ther. 17:117-124. http://dx.doi.org/10.1089/hum.2006.17.117.
12. Selvam MP, Buck SM, Blay RA, Mayner RE, Mied PA, Epstein JS. 1996. Inhibition of HIV replication by immunoliposomal antisense oligonucleotide. Antiviral Res. 33:11-20.
13. Wen WH, Liu JY, Qin WJ, Zhao J, Wang T, Jia LT, Meng YL, Gao H, Xue CF, Jin BQ, Yao LB, Chen SY, Yang AG. 2007. Targeted inhibition of HBV gene expression by single-chain antibody mediated small interfering RNA delivery. Hepatology 46:84-94. http://dx.doi.org/10.1002/hep.21663.
14. Ge Q, McManus MT, Nguyen T, Shen CH, Sharp PA, Eisen HN, Chen J. 2003. RNA interference of influenza virus production by directly targeting mRNA for degradation and indirectly inhibiting all viral RNA transcription. Proc. Natl. Acad. Sci. U. S. A. 100:2718-2723. http://dx.doi.org/10.1073/pnas.0437841100.
15. Messerschmidt SK, Kolbe A, Muller D, Knoll M, Pleiss J, Kontermann RE. 2008. Novel single-chain Fv= formats for the generation of immunoliposomes by site-directed coupling. Bioconjug. Chem. 19:362-369. http://dx.doi.org/10.1021/ bc700349k.
16. Gao J, Sun J, Li H, Liu W, Zhang Y, Li B, Qian W, Wang H, Chen J, Guo Y. 2010. Lyophilized HER2-specific PEGylated immunoliposomes for active siRNA gene silencing. Biomaterials 31:2655-2664. http://dx.doi.org/10.1016/j.biomaterials. 2009.11.112.
17. Adrian JE, Kamps JA, Scherphof GL, Meijer DK, van Loenen-Weemaes AM, Reker-Smit C, Terpstra P, Poelstra K. 2007. A novel lipid-based drug carrier targeted to the non-parenchymal cells, including hepatic stel-late cells, in the fibrotic livers of bile duct ligated rats. Biochim. Biophys. Acta 1768:1430-1439. http://dx.doi.org/10.1016/j.bbamem.2007.03.027.
18. Peer D, Park EJ, Morishita Y, Carman CV, Shimaoka M. 2008. Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an antiinflammatory target. Science 319:627-630. http://dx.doi.org/10.1126/science.1149859.
19. Wang K, Holtz KM, Anderson K, Chubet R, Mahmoud W, Cox MM. 2006. Expression and purification of an influenza hemagglutinin: one step closer to a recombinant protein-based influenza vaccine. Vaccine 24: 2176-2185. http://dx.doi.org/10.1016/j.vaccine.2005.11.005.
20. Stoddart MJ. 2011. Cell viability assays: introduction. Methods Mol. Biol. 740:1-6. http://dx.doi.org/10.1007/978-1-61779-108-6-1.
21. Reed LJ, Muench H. 1938. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 27:493-497.
22. Lu L, Yu L, Kwang J. 2007. Baculovirus surface-displayed hemagglutinin of H5N1 influenza virus sustains its authentic cleavage, hemagglutination activity, and antigenicity. Biochem. Biophys. Res. Commun. 358:404-409. http://dx.doi.org/10.1016/j.bbrc.2007.04.148.
23. Ahmad ZA, Yeap SK, Ali AM, Ho WY, Alitheen NB, Hamid M. 2012. scFv antibody: principles and clinical application. Clin. Dev. Immunol. 2012:980250. http://dx.doi.org/10.1155/2012/980250.
24. Kim SJ, Park Y, Hong HJ. 2005. Antibody engineering for the development of therapeutic antibodies. Mol. Cell 20:17-29.
25. Norley SG, Huang L, Rouse BT. 1986. Targeting of drug loaded immunoliposomes to herpes simplex virus infected corneal cells: an effective means of inhibiting virus replication in vitro. J. Immunol. 136:681-685.
26. Zhou Y, Drummond DC, Zou H, Hayes ME, Adams GP, Kirpotin DB, Marks JD. 2007. Impact of single-chain Fv antibody fragment affinity on nanoparticle targeting of epidermal growth factor receptor-expressing tumor cells. J. Mol. Biol. 371:934-947. http://dx.doi.org/10.1016/j.jmb.200 7.05.011.
27. Nielsen UB, Adams GP, Weiner LM, Marks JD. 2000. Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity. Cancer Res. 60:6434-6440. http://cancerres. aacrjournals.org/content/60/22/6434.full.pdf.
28. Volkel T, Holig P, Merdan T, Muller R, Kontermann RE. 2004. Targeting of immunoliposomes to endothelial cells using a single-chain Fv fragment directed against human endoglin (CD105). Biochim. Biophys. Acta 1663:158-166. http://dx.doi.org/10.1016/j.bbamem.2004.03.007.
29. Gao X, Huang L. 1991. A novel cationic liposome reagent for efficient transfection of mammalian cells. Biochem. Biophys. Res. Commun. 179: 280-285.
30. Huang A, Kennel SJ, Huang L. 1983. Interactions of immunoliposomes with target cells. J. Biol. Chem. 258:14034-14040.
31. Zhang T, Wang CY, Zhang W, Gao YW, Yang ST, Wang TC, Zhang RZ, Qin C, Xia XZ. 2010. Generation and characterization of a fusion protein of single-chain fragment variable antibody against hemagglutinin antigen of avian influenza virus and truncated protamine. Vaccine 28:3949-3955. http://dx.doi.org/10.1016/ j.vaccine.2010.03.045.
32. Zhang Z, Zhang J, Huang K, Li KS, Yuen KY, Guan Y, Chen H, Ng WF. 2009. Systemic infection of avian influenza A virus H5N1 subtype in humans. Hum. Pathol. 40:735-739. http://dx.doi.org/10.1016/j.humpath.2008.08.015.
33. Tompkins SM, Lo CY, Tumpey TM, Epstein SL. 2004. Protection against lethal influenza virus challenge by RNA interference in vivo. Proc. Natl. Acad. Sci. U. S. A. 101:8682-8686. http://dx.doi.org/10.1073/pnas.0402630101.
34. Zhang W, Wang CY, Yang ST, Qin C, Hu JL, Xia XZ. 2009. Inhibition of highly pathogenic avian influenza virus H5N1 replication by the small interfering RNA targeting polymerase A gene. Biochem. Biophys. Res. Commun. 390:421-426. http://dx.doi.org/10.1016/j.bbrc.2009.09.039.
35. Zhou H, Jin M, Yu Z, Xu X, Peng Y, Wu H, Liu J, Liu H, Cao S, Chen H. 2007. Effective small interfering RNAs targeting matrix and nucleocapsid protein gene inhibit influenza A virus replication in cells and mice. Antiviral Res. 76:186-193. http://dx.doi.org/10.1016/j.antiviral. 2007.07.002.
36. Hughey PG, Compans RW, Zebedee SL, Lamb RA. 1992. Expression of the influenzaAvirusM2protein is restricted to apical surfaces of polarized epithelial cells. J. Virol. 66:5542-5552.
37. Chen Y, Qin K, Wu WL, Li G, Zhang J, Du H, Ng MH, Shih JW, Peiris JS, Guan Y, Chen H, Xia N. 2009. Broad cross-protection against H5N1 avian influenza virus infection by means of monoclonal antibodies that map to conserved viral epitopes. J. Infect. Dis. 199:49-58. http://dx.doi.org/10.1086/594374.
38. Bass BL. 2000. Double-stranded RNA as a template for gene silencing. Cell 101:235-238. http://dx.doi.org/10.1016/S0092-8674(02)71133-1.
39. Du Q, Thonberg H, Wang J, Wahlestedt C, Liang Z. 2005. A systematic analysis of the silencing effects of an active siRNA at all single-nucleotide mismatched target sites. Nucleic Acids Res. 33:1671-1677. http://dx.doi.org/10. 1093/nar/gki312.
40. Holen T, Amarzguioui M, Wiiger MT, Babaie E, Prydz H. 2002. Positional effects of short interfering RNAs targeting the human coagulation trigger Tissue Factor. Nucleic Acids Res. 30:1757-1766. http://dx.doi.org/10.1093/nar/30.8. 1757.